

Robert Deans

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10467210/publications.pdf>

Version: 2024-02-01

42
papers

5,528
citations

201575

27
h-index

265120

42
g-index

45
all docs

45
docs citations

45
times ranked

5893
citing authors

#	ARTICLE	IF	CITATIONS
1	Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo. <i>Experimental Hematology</i> , 2002, 30, 42-48.	0.2	2,084
2	Human mesenchymal stem cells engraft and demonstrate site-specific differentiation after in utero transplantation in sheep. <i>Nature Medicine</i> , 2000, 6, 1282-1286.	15.2	1,161
3	Mesenchymal stem cells are capable of homing to the bone marrow of non-human primates following systemic infusion. <i>Experimental Hematology</i> , 2001, 29, 244-255.	0.2	393
4	Bioenergetic and Functional Consequences of Bone Marrow-Derived Multipotent Progenitor Cell Transplantation in Hearts With Postinfarction Left Ventricular Remodeling. <i>Circulation</i> , 2007, 115, 1866-1875.	1.6	248
5	Baboon Mesenchymal Stem Cells Can Be Genetically Modified to Secrete Human Erythropoietin In Vivo. <i>Human Gene Therapy</i> , 2001, 12, 1527-1541.	1.4	157
6	Intravenous multipotent adult progenitor cell therapy for traumatic brain injury: Preserving the blood brain barrier via an interaction with splenocytes. <i>Experimental Neurology</i> , 2010, 225, 341-352.	2.0	133
7	Soliciting Strategies for Developing Cell-Based Reference Materials to Advance Mesenchymal Stromal Cell Research and Clinical Translation. <i>Stem Cells and Development</i> , 2014, 23, 1157-1167.	1.1	112
8	Human Multipotent Adult Progenitor Cells Are Nonimmunogenic and Exert Potent Immunomodulatory Effects on Alloreactive T-Cell Responses. <i>Cell Transplantation</i> , 2013, 22, 1915-1928.	1.2	83
9	Clinical-Grade Multipotent Adult Progenitor Cells Durably Control Pathogenic T Cell Responses in Human Models of Transplantation and Autoimmunity. <i>Journal of Immunology</i> , 2013, 190, 4542-4552.	0.4	72
10	Development of a surrogate angiogenic potency assay for clinical-grade stem cell production. <i>Cytotherapy</i> , 2012, 14, 994-1004.	0.3	70
11	Advancement of Mesenchymal Stem Cell Therapy in Solid Organ Transplantation (MISOT). <i>Transplantation</i> , 2010, 90, 124-126.	0.5	66
12	Application of MultiStem® Allogeneic Cells for Immunomodulatory Therapy: Clinical Progress and Pre-Clinical Challenges in Prophylaxis for Graft Versus Host Disease. <i>Frontiers in Immunology</i> , 2012, 3, 345.	2.2	66
13	Toward MSC in Solid Organ Transplantation: 2008 Position Paper of the MISOT Study Group. <i>Transplantation</i> , 2009, 88, 614-619.	0.5	64
14	Harmonizing standards for producing clinical-grade therapies from pluripotent stem cells. <i>Nature Biotechnology</i> , 2014, 32, 724-726.	9.4	62
15	Global Characterization and Genomic Stability of Human MultiStem, A Multipotent Adult Progenitor Cell. <i>Journal of Stem Cells</i> , 2009, 4, 17-28.	1.0	57
16	Clinical scale expanded adult pluripotent stem cells prevent graft-versus-host disease. <i>Cellular Immunology</i> , 2009, 255, 55-60.	1.4	53
17	Multipotent adult progenitor cells decrease cold ischemic injury in ex vivo perfused human lungs: an initial pilot and feasibility study. <i>Transplantation Research</i> , 2014, 3, 19.	1.5	52
18	Safety and feasibility of third-party multipotent adult progenitor cells for immunomodulation therapy after liver transplantation--a phase I study (MISOT-I). <i>Journal of Translational Medicine</i> , 2011, 9, 124.	1.8	51

#	ARTICLE	IF	CITATIONS
19	Development of adult pluripotent stem cell therapies for ischemic injury and disease. Expert Opinion on Biological Therapy, 2007, 7, 173-184.	1.4	50
20	Heart Grafts Tolerized Through Third-Party Multipotent Adult Progenitor Cells Can Be Retransplanted to Secondary Hosts With No Immunosuppression. Stem Cells Translational Medicine, 2013, 2, 595-606.	1.6	50
21	Percutaneous Adventitial Delivery of Allogeneic Bone Marrow-Derived Stem Cells via Infarct-Related Artery Improves Long-Term Ventricular Function in Acute Myocardial Infarction. Cell Transplantation, 2012, 21, 1109-1120.	1.2	45
22	Therapeutic pathways of adult stem cell repair. Critical Reviews in Oncology/Hematology, 2008, 65, 81-93.	2.0	42
23	Human adult bone marrow-derived stem cells decrease severity of lipopolysaccharide-induced acute respiratory distress syndrome in sheep. Stem Cell Research and Therapy, 2014, 5, 42.	2.4	40
24	Suppression of IL-7-dependent Effector T-cell Expansion by Multipotent Adult Progenitor Cells and PGE2. Molecular Therapy, 2015, 23, 1783-1793.	3.7	40
25	Transplantation of Cryopreserved Human Bone Marrow-derived Multipotent Adult Progenitor Cells for Neonatal Hypoxic-Ischemic Injury: Targeting the Hippocampus. Reviews in the Neurosciences, 2006, 17, 215-25.	1.4	30
26	Multipotent adult progenitor cells for hypoxic-ischemic injury in the preterm brain. Journal of Neuroinflammation, 2015, 12, 241.	3.1	29
27	Additional Restriction Endonuclease Cleavage Sites on the Bacteriophage P22 Genome. Journal of Virology, 1983, 45, 864-867.	1.5	29
28	Multipotent adult progenitor cells on an allograft scaffold facilitate the bone repair process. Journal of Tissue Engineering, 2016, 7, 204173141665614.	2.3	20
29	Neuroinflammatory signals enhance the immunomodulatory and neuroprotective properties of multipotent adult progenitor cells. Stem Cell Research and Therapy, 2015, 6, 176.	2.4	19
30	Adult adherent cell therapy for ischemic stroke: clinical results and development experience using MultiStem. Transfusion, 2016, 56, 6S-8S.	0.8	14
31	Towards the creation of a standard MSC line as a calibration tool. Cytotherapy, 2015, 17, 1167-1168.	0.3	12
32	Manufacturing Cells for Clinical Use. Stem Cells International, 2016, 2016, 1-5.	1.2	8
33	Culturing Protocols for Human Multipotent Adult Stem Cells. Methods in Molecular Biology, 2015, 1235, 49-58.	0.4	8
34	Regulation, manufacturing and building industry consensus. Regenerative Medicine, 2012, 7, 78-81.	0.8	7
35	Multipotent Adult Progenitor Cells. , 2007, , 45-56.		7
36	Augmented Expansion of Treg Cells From Healthy and Autoimmune Subjects via Adult Progenitor Cell Co-Culture. Frontiers in Immunology, 2021, 12, 716606.	2.2	6

#	ARTICLE	IF	CITATIONS
37	Crosstalk with Inflammatory Macrophages Shapes the Regulatory Properties of Multipotent Adult Progenitor Cells. <i>Stem Cells International</i> , 2017, 2017, 1-16.	1.2	4
38	Human Multipotent Adult Progenitor Cells Effectively Reduce Graft-vs-Host Disease While Preserving Graft-Vs-Leukemia Activity. <i>Stem Cells</i> , 2021, 39, 1506-1519.	1.4	4
39	Commercialization of trials for peripheral artery disease. <i>Cytotherapy</i> , 2011, 13, 1157-1161.	0.3	3
40	Clinical Scale Expansion of Human Pluripotent Stem Cells.. <i>Blood</i> , 2005, 106, 1060-1060.	0.6	3
41	Cellular Therapy for Myocardial Repair. <i>Current Cardiology Reviews</i> , 2007, 3, 121-135.	0.6	1
42	Bringing Mesenchymal Stem Cells into the Clinic. , 0, , 463-481.		0